All Stories

Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through

Halozyme is not holding back against Merck & Co. in their injectable Keytruda patent dispute, having now followed through on a verbal warning with a lawsuit.

Apr 24, 2025 - 20:13
 0
Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through
Halozyme is not holding back against Merck & Co. in their injectable Keytruda patent dispute, having now followed through on a verbal warning with a lawsuit.
Read More

Tags:

Previous Article

[OFFER BEING PULLED]: The No Annual Fee Card That Makes Your Spending More Valua...

Next Article

Knight-Swift, Union Pacific brace for West Coast volume downturn

Related Posts

Novartis plans 427 layoffs as looming Entresto patent cliff sparks marketing refresh

Novartis plans 427 layoffs as looming Entresto patent c...

Mar 21, 2025  0

Gilead sets aside $200M for potential settlement over HIV drug speaker program

Gilead sets aside $200M for potential settlement over H...

Mar 4, 2025  0

Eli Lilly CEO on Trump's tariffs: 'It'll be hard to come back from here'

Eli Lilly CEO on Trump's tariffs: 'It'll be hard to com...

Apr 4, 2025  0